Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.53 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132089 | 1.00 | SLC6A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL132090 | 1.00 | SLC6A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5215224 | 0.98 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL22444028 | 0.98 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL205293 | 0.98 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL14525966 | 0.95 | ALDH1A1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL29295425 | 0.93 | ALDH1A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Chloroacetic Acid SCHEMBL27501180 | 0.91 | SLC6A1 (0.49) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Cadaverine Tartrate SCHEMBL4889376 | 0.89 | SLC6A1 (0.47) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Cadaverine Tartrate SCHEMBL6970212 | 0.89 | SLC6A1 (0.47) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184650-A | 6- (1H-pyrrolo [2,3-b ] pyridin-3-yl) quinazoline-4-amine derivative, and preparation method and application thereof | 中国人民解放军北部战区总医院 | 2024-06-14 | — | — | CN | claimed |
| CN-116947879-A | BBI608 derivative, preparation method thereof and application thereof in preparing medicines for treating STAT3 mediated diseases | 沈阳药科大学 | 2023-10-27 | — | — | CN | claimed |
| CN-113402447-B | sEH inhibitor or pharmaceutically acceptable composition thereof, and preparation method and application thereof | 沈阳药科大学 | 2022-10-18 | — | — | CN | claimed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12617797-B2 | Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2026-05-05 | — | — | US | disclosed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| EP-4648851-A1 | SUBSTITUTED (HETERO)ANILINES AND THEIR USE | Astrazeneca AB (SE) | 2025-11-19 | — | — | EP | disclosed |
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4620951-A1 | MEMANTINE UREA DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING SOLUBLE EPOXIDE ENZYME-MEDIATED DISEASES | Shenyang Pharmaceutical University (CN) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025149498-A1 | BENZYLPIPERIDINE DERIVATIVES AS TRP4 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | disclosed |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| EP-1313725-B1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1694644-A2 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058824-A2 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTE IN B | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-30 | — | — | WO | disclosed |
| US-6127366-A | ANTICARCINOGENIC OR ANTITUMOR AGENTS | MERCK & CO., INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0862435-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | disclosed |
| US-5817678-A | IMIDAZOLE-CONTAINING PIPERIDINE DERIVATIVES, PEPTIDEMIMETIC | MERCK & CO., INC. (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0862435-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997018813-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | SLC6A1 3746/4885SLC6A11 3929/4885TSHR 256/4885 |
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | POLRMT, TFAM, POLM | SLC6A1 4781/4885SLC6A11 4812/4885TSHR 2586/4885 |
| US-12617797-B2 | Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain | SIGMAR1, OPRD1, OPRL1 | SLC6A1 348/4885SLC6A11 336/4885TSHR 818/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | SLC6A1 3012/4885SLC6A11 3381/4885TSHR 70/4885 |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | APOB, PNLIP, LIPC | SLC6A1 3895/4885SLC6A11 3590/4885TSHR 2816/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | SLC6A1 2120/4885SLC6A11 1826/4885TSHR 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.